American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Temin
Sarah
S
American Society of Clinical Oncology, Cancer Policy and Clinical Affairs Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D017313:Fenretinide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
D047072:Aromatase Inhibitors; D013629:Tamoxifen; D017313:Fenretinide; D020849:Raloxifene Hydrochloride